Now Reading
Psychedelic Business and Investment News: April 5-9

Psychedelic Business and Investment News: April 5-9

Psychedelic Business and Investment News Roundup Stock Image

Truffle Report has compiled a roundup of major psychedelic business and investment news from April 5-9, making it easier for you to access these insights in one place.

Tryp Therapeutics

On April 5, Tryp Therapeutics announced that it has been approved to list on the OTCQB Venture Market and with The Depository Trust Company (DTC). Tryp’s common shares are currently traded under the symbol “TRYPF” on the OTCQB and will continue to trade on the Canadian Securities Exchange under the symbol “TRYP.”

“We are pleased to have initiated the quoting of our common shares on the OTCQB. This important step increases access to our shares to a wider range of institutional and retail investors in the United States. I am excited for these new investors to become familiar with the important scientific and clinical work we are doing to develop leading-edge therapies for millions of patients suffering from chronic pain, rare eating disorders, and soft tissue sarcomas through our synthetic psilocybin and razoxane programs,” said Greg McKee, CEO of Tryp.

Optimi Health

On April 6, Optimi Health Corp., a Vancouver-based functional mushroom company that focuses on the wellness and health sector, announced that it has been added to the German Börse Frankfurt (FRA) exchange platform and is now listed under the symbol 8BN and registered under WKN: A2QQEL and/or ISIN: CA68405H1001. Optimi Health will now be actively pursuing DTC eligibility to allow the electronic movement of shares as well as an application to list on OTC Markets QB equity exchange.

“Today’s news is an important milestone towards broadening our market presence overseas as well as shortly within the United States. As our operations continue to grow and develop it’s important to ensure our shareholder audience can grow with us,” said Michael Stier, CEO of Optimi Health Corp.

Newscope Capital Corporation

On April 8, Newscope Capital Corporation announced that it has changed its name to PharmaTher Holdings Ltd. It will be filing the necessary documentation with the CSE to commence trading under its new name. There is no change in the share capital or its trading symbol, and shareholders are not required to exchange their existing share certificates for new certificates.

Havn Life Sciences

On April 8, Havn Life announced that it has completed the acquisition of GCO Packaging and Manufacturing Ltd., acquiring 100 percent of the outstanding shares of GCO in exchange for an aggregate of 6,000,000 common shares of Havn Life.

See Also
LSD Neutralizer Graphic

“Acquisition of this facility represents a pivotal step forward for us, as we ramp up production of the seven natural health products we’re launching this spring in retailers such as Nesters Market. Our team continues to work towards formulating and developing new and innovative products to bring to market. Looking to the future, it will also enable us to produce a range of new products, from functional teas to other natural health product formulations,” said Tim Moore, CEO of Havn Life.

Mind Cure Health

On April 8, Mind Cure Health announced an additional equity investment in ATMA Journey Centers. This follow-on investment enables Mind Cure to retain its 13 percent ownership of ATMA, following the terms of the letter of intent announced on January 12, 2021. Mind Cure’s President and CEO Kelsey Ramsden will be joining the ATMA Board of Directors.

“We are extremely excited to strengthen our partnership with the team at ATMA through this investment. This further solidifies the company’s strategic position in clinics and partnerships for the deployment of digital therapeutics to drive near-term revenues. ATMA’s team is a true pioneer in the psychedelic therapy industry by growing a global network of group and retreat psychedelic therapy clinics,” said Ramsden. “ATMA’s established clinical footprint gives us the opportunity to deploy our iSTRYM technology, with the intended goal to optimize treatment for ATMA’s patients and obtain the data we need to build iSTRYM into the platform trusted by therapists and patients around the world.”

View Comments (0)

Leave a Reply

Your email address will not be published.

Scroll To Top